Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Erlotinib hydrochloride (ERLO) belongs to the tyrosine kinase inhibitor family and is used for
the treatment of pancreatic cancers. In the present study, ERLO was entrapped in lipid …

Lung cancer is characterized by poor prognosis, and is considered a serious disease that
causes a significant mortality. The available conventional chemotherapeutic agents suffer …

The present research work was aimed to explore the ability of nanostructured lipid carriers
(NLCs) to improve oral bioavailability of Nintedanib esylate (NE) via lymphatic uptake. The …

Introduction and objective Lung cancer is the most common one in terms of outbreak and
mortality. Since most modern treatments have many side effects, finding an effective and …

Context: Cardiotoxicity and myelosuppression of etoposide (ETP) limited its clinical
application. Targeted drug delivery system could deliver anticancer agents to the target …

Synergistic effects of multiple drugs with different modes of action are utilized for
combinatorial chemotherapy of intractable cancers. Translation of in vitro synergistic effects …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Gefitinib (GEF) is the first-line therapy for lung cancer. Mebendazole (MBZ) is a synthetic
antiparasite drug with reported cytotoxicity against lung cancer through Ran GTPase …

This contribution is focused on the preparation of a liposomal drug delivery system of
erlotinib resisting the nebulization process that could be used for local treatment of non …